An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.

Summary

This is a research study to evaluate the efficacy and safety of the investigational drug Mitiperstat (AZD4831) in adult patients with chronic obstructive pulmonary disease.

Timeline

Start

2022-11-14

Primary completion

2024-08-12

Completion

2024-08-12

Outcome

Missed primary endpoint

registry analysis (superiority test); Mitiperstat vs Placebo; p = 0.599; Hazard Ratio (HR) 1.071 (90% CI 0.869 to 1.320); Regression, Cox NCT05492877 ↗

Publications

• Dijk L, Driessen MMG, Gerritsma YH, Bolton C, Da Silva C, Kocks JWH. How do acute worsening events influence daily life and healthcare-seeking behaviour in patients with COPD: an international multicountry qualitative study. BMJ Open. 2026 Jun 11;16(6):e104245. doi: 10.1136/bmjopen-2025-104245.

Drugs

Indications